Australian Life Scientists acquired by specialist laboratory publisher
15 November, 2012 by Staff WritersAustralian Life Scientist magazine, and its sister website www.lifescientist.com.au, have been acquired by Westwick-Farrow Media (WFM), and will join its stable of B2B magazines and websites, including What’s New in Lab & Life Sciences.
AmpliPhi and SPS complete merger
15 November, 2012 by Dylan Bushell-EmblingAustralia's Special Phage Services is now part of US-based AmpliPhi, following the closure of a merger between the two bacteriophage companies.
New project to support life sciences boards and directors
15 November, 2012 by AusBiotechAusBiotech, with support from the Victorian Government, has begun a project to support board and directors’ development and promote best practice reporting and governance.
Funding difficulties see Avexa turn to mining
14 November, 2012 by Dylan Bushell-EmblingAvexa (ASX:AVX) is committing most of its cash to an investment in a US coal mine to generate cash for development of its clinical programs including HIV drug ATC.
Encouraging trial results for Prima’s ovarian cancer treatment
14 November, 2012 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has published a second set of encouraging early data from a phase II trial of CVac in ovarian cancer
Viralytics R&D Tax rebate higher than expected
13 November, 2012 by Dylan Bushell-EmblingViralytics (ASX:VLA) has received nearly $1.5m as an R&D Tax Incentive rebate, and will plough the funds back into its oncolytic virus clinical development.
Vic Gov launches Technology Voucher Program
13 November, 2012 by AusBiotechGrowing on the success of the “Small Technologies Industry Uptake Program” the Victorian Government has launched a new “Technology Voucher Program” (TVP).
Biotron up after phase II HIV/HCV trial kicks off
12 November, 2012 by Dylan Bushell-EmblingBiotron (ASX:BIT) has commenced a pivotal phase II trial of BIT225 in patients with both HIV and HCV.
Viralytics trial shows Cavatak well-tolerated
12 November, 2012 by Dylan Bushell-EmblingViralyrics (ASX:VLA) has published results from a phase I trial showing anti-cancer virus, Cavatak, show the treatment was well-tolerated.
Photonz seeking partners to develop drug manufacturing process
12 November, 2012 by Dylan Bushell-EmblingAfter years in development, New Zealand's Photonz is embarking on the hunt for partners to help commercialise its manufacturing process for a key cardiovascular drug component.
BioDiem, Griffith Uni team for BDM-1 research
09 November, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) will collaborate with Griffith University's Institute of Glycomics to explore increasing the solubility of antimicrobial compound BDM-1.
Government IP report promotes research and business collaboration
09 November, 2012 by Tim DeanA report issued today by the Advisory Council on Intellectual Property has recommended reforming incentives to encourage researchers to collaborate with business.
DSMB clears Alchemia to continue cancer trial
08 November, 2012 by Dylan Bushell-EmblingThe DSMB overseeing Alchemia's phase III trial of HA-Irinotecan in metastatic colorectal cancer has recommended the trial continue on the strength of existing safety data.
IND lodged for Bionomics anxiety compound
08 November, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) US partner, Ironwood Pharmaceuticals, has lodged an Investigational New Drug application with the US FDA for anti-anxiety compound IW-2143 and has the go-ahead to conduct a phase I trial.
Australian biotech looking ‘healthy’ as it gathers for AusBiotech 2012
08 November, 2012 by AusBiotechThe AusBiotech 2012 national conference has again showcased the great talent and intellectual capital within Australia’s biotechnology industry.
